Top Suppliers:I want be here

210829-30-4

210829-30-4 structure
210829-30-4 structure
  • Name: Gemcitabine elaidate
  • Chemical Name: [(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
  • CAS Number: 210829-30-4
  • Molecular Formula: C27H43F2N3O5
  • Molecular Weight: 527.644
  • Catalog: Signaling Pathways Autophagy Autophagy
  • Create Date: 2016-10-13 08:28:30
  • Modify Date: 2024-01-05 06:46:57
  • Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.IC50 value:Target: Gemcitabine analogUpon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. Check for active clinical trials or closed clinical trials using this agent.

Name [(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
Synonyms Gemcitabine elaidate [INN]
2'-Deoxy-2',2'-difluoro-5'-O-[(9E)-9-octadecenoyl]cytidine
CO-101
UNII-231C73W7LG
Gemcitabine elaidate
CP-4126
Gemcitabine elaidate (USAN/INN)
Cytidine, 2'-deoxy-2',2'-difluoro-5'-O-[(9E)-1-oxo-9-octadecen-1-yl]-
Gemcitabine (elaidate)
Description Gemcitabine elaidate(CP-4126; CO-101) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.IC50 value:Target: Gemcitabine analogUpon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. Check for active clinical trials or closed clinical trials using this agent.
Related Catalog
Density 1.2±0.1 g/cm3
Boiling Point 631.4±65.0 °C at 760 mmHg
Molecular Formula C27H43F2N3O5
Molecular Weight 527.644
Flash Point 335.7±34.3 °C
Exact Mass 527.317078
PSA 117.66000
LogP 7.70
Vapour Pressure 0.0±4.2 mmHg at 25°C
Index of Refraction 1.536
Storage condition 2-8℃